Passion and commitment coming together to innovate and accelerate pancreatic cancer research.

Passion and commitment coming together to innovate and accelerate pancreatic cancer research.

Discover Clinical Trials Supported by the Pancreatic Cancer Collective

The Pancreatic Cancer Collective is accelerating research for pancreatic cancer patients who desperately need better treatments. If you or a loved one have been diagnosed with pancreatic cancer, check with your doctor if you’re eligible for a clinical trial.

Learn more about specific Lustgarten Foundation and Stand Up To Cancer-supported clinical trials by utilizing our clinical trial finder below.

ARIZONACALIFORNIACOLORADOMARYLANDMASSACHUSETTSMISSOURINEW YORKOREGONPENNSYLVANIATENNESSEETEXASUTAH

ARIZONA

City: Scottsdale
Institution: HonorHealth Research Institute
Trial Name: A Study of Cabiralizumab Given With Nivolumab With and Without Chemotherapy in Patients With Advanced Pancreatic Cancer.
Learn More

City: Phoenix
Institution: Mayo Clinic Cancer Center
Trial Name: A Study of Cabiralizumab Given With Nivolumab With and Without Chemotherapy in Patients With Advanced Pancreatic Cancer.
Learn More

City: Scottsdale
Institution: HonorHealth
Trial Names: A Study of Cabiralizumab Given With Nivolumab With and Without Chemotherapy in Patients With Advanced Pancreatic Cancer.
Learn More

CALIFORNIA

City: Los Angeles
Institution: University of Los Angeles
Trial Name: A Study of Cabiralizumab Given With Nivolumab With and Without Chemotherapy in Patients With Advanced Pancreatic Cancer.
Learn More

City: San Diego
Institution: University of California San Diego
Trial Name: A phase II, international open label trial of Minnelide™ in patients with refractory pancreatic cancer.
Learn More

City: Stanford(Closed)
Institution: Stanford University
Trial Name: A Randomized Phase 2 Study of the Safety, Efficacy, and Immune Response of GVAX Pancreas Vaccine (with Cyclophosphamide) and CRS-207 with or without Nivolumab in Patients with Previously Treated Metastatic Pancreatic Adenocarcinoma.
Learn More

City: San Francisco(Closed)
Institution: UCSF Helen Diller Family Comprehensive Cancer Center
Trial Name: Ibrutinib Combined With Gemcitabine and Nab-Paclitaxel in Patients With Metastatic Pancreatic Cancer (144525).
Learn More

COLORADO

City: Aurora
Institution: University of Colorado Cancer Center
Trial Name: A three arm, 40 patient per arm Phase II study is proposed to evaluate neoadjuvant 1) FOLFIRINOX and SBRT 2) addition of losartan and 3) addition of losartan and anti-PD1.
Learn More

City: Aurora
Institution: University of Colorado Cancer Center
Trial Name: A Study of Cabiralizumab Given With Nivolumab With and Without Chemotherapy in Patients With Advanced Pancreatic Cancer.
Learn More

MARYLAND

City: Baltimore
Institution: Johns Hopkins
Trial Name: A Study of Cabiralizumab Given With Nivolumab With and Without Chemotherapy in Patients With Advanced Pancreatic Cancer.
Learn More

City: Baltimore(Closed)
Institution: Johns Hopkins
Trial Name: A Randomized Phase 2 Study of the Safety, Efficacy, and Immune Response of GVAX Pancreas Vaccine (with Cyclophosphamide) and CRS-207 with or without Nivolumab in Patients with Previously Treated Metastatic Pancreatic Adenocarcinoma.
Learn More

City: Baltimore(Closed)
Institution: Sidney Kimmel Cancer Center
Trial Name: A Randomized Phase 2 Study of the Safety, Efficacy, and Immune Response of GVAX Pancreas Vaccine (with Cyclophosphamide) and CRS-207 with or without Nivolumab in Patients with Previously Treated Metastatic Pancreatic Adenocarcinoma.
Learn More

MASSACHUSETTS

City: Boston
Institution: Beth Israel Deaconess Medical Center
Trial Names: A three arm, 40 patient per arm Phase II study is proposed to evaluate neoadjuvant 1) FOLFIRINOX and SBRT 2) addition of losartan and 3) addition of losartan and anti-PD1.
Learn More

City: Boston
Institution: Brigham and Women’s Hospital
Trial Names: A three arm, 40 patient per arm Phase II study is proposed to evaluate neoadjuvant 1) FOLFIRINOX and SBRT 2) addition of losartan and 3) addition of losartan and anti-PD1.
Learn More

City: Boston
Institution: Dana Farber Cancer Institute
Trial Names: A three arm, 40 patient per arm Phase II study is proposed to evaluate neoadjuvant 1) FOLFIRINOX and SBRT 2) addition of losartan and 3) addition of losartan and anti-PD1.
Learn More

City: Boston
Institution: Massachusetts General Hospital
Trial Names: A three arm, 40 patient per arm Phase II study is proposed to evaluate neoadjuvant 1) FOLFIRINOX and SBRT 2) addition of losartan and 3) addition of losartan and anti-PD1.
Learn More

City: Boston
Institution: Newton Wellesley Hospital
Trial Names: A three arm, 40 patient per arm Phase II study is proposed to evaluate neoadjuvant 1) FOLFIRINOX and SBRT 2) addition of losartan and 3) addition of losartan and anti-PD1.
Learn More

MISSOURI

City: St. Louis
Institution: Washington University
Trial Names: A Study of Cabiralizumab Given With Nivolumab With and Without Chemotherapy in Patients With Advanced Pancreatic Cancer.
Learn More

NEW YORK

City: New York City
Institution: Memorial Sloan Kettering
Trial Names: A Study of Cabiralizumab Given With Nivolumab With and Without Chemotherapy in Patients With Advanced Pancreatic Cancer.
Learn More

City: New York City
Institution: New York University Langone Medical Center
Trial Names: A three arm, 40 patient per arm Phase II study is proposed to evaluate neoadjuvant 1) FOLFIRINOX and SBRT 2) addition of losartan and 3) addition of losartan and anti-PD1.
Learn More

OREGON

City: Portland(Closed)
Institution: Oregon Health and Science University
Trial Names: Ibrutinib Combined With Gemcitabine and Nab-Paclitaxel in Patients With Metastatic Pancreatic Cancer (144525).
Learn More

City: Portland(Closed)
Institution: Providence Portland Medical Center
Trial Names: A Randomized Phase 2 Study of the Safety, Efficacy, and Immune Response of GVAX Pancreas Vaccine (with Cyclophosphamide) and CRS-207 with or without Nivolumab in Patients with Previously Treated Metastatic Pancreatic Adenocarcinoma.
Learn More

PENNSYLVANIA

City: Philadelphia
Institution: University of Pennsylvania
Trial Name: UPCC# 14217 Phase I study of human CAR modified T cells in patients with pancreatic cancer.
Learn More

City: Philadelphia
Institution: University of Pennsylvania
Trial Name: A phase II, international open label trial of Minnelide™ in patients with refractory pancreatic cancer.
Learn More

City: Philadelphia
Institution: University of Pennsylvania
Trial Name: A Study of Cabiralizumab Given With Nivolumab With and Without Chemotherapy in Patients With Advanced Pancreatic Cancer.
Learn More

City: Pittsburgh
Institution: UPMC
Trial Name: A Study of Cabiralizumab Given With Nivolumab With and Without Chemotherapy in Patients With Advanced Pancreatic Cancer.
Learn More

City: Philadelphia(Closed)
Institution: University of Pennsylvania
Trial Name: A Randomized Phase 2 Study of the Safety, Efficacy, and Immune Response of GVAX Pancreas Vaccine (with Cyclophosphamide) and CRS-207 with or without Nivolumab in Patients with Previously Treated Metastatic Pancreatic Adenocarcinoma.
Learn More

TENNESSEE

City: Nashville
Institution: Tennessee Oncology
Trial Names: A Study of Cabiralizumab Given With Nivolumab With and Without Chemotherapy in Patients With Advanced Pancreatic Cancer.
Learn More

TEXAS

City: Dallas
Institution: UT Southwestern
Trial Names: A clinical trial of the AXL-inhibitor BGB324 plus chemotherapy with nabpaclitaxel.
Learn More

City: Dallas
Institution: UT Southwestern
Trial Names: A Study of Cabiralizumab Given With Nivolumab With and Without Chemotherapy in Patients With Advanced Pancreatic Cancer.
Learn More

City: Houston
Institution: M.D. Anderson Cancer Center
Trial Names: A Study of Cabiralizumab Given With Nivolumab With and Without Chemotherapy in Patients With Advanced Pancreatic Cancer.
Learn More

UTAH

City: Salt Lake City
Institution: Huntsman Cancer Institute/University of Utah
Trial Names: Trametinib and Hydroxychloroquine in Treating Patients With Pancreatic Cancer (THREAD).
Learn More